COPD: Journal of Chronic Obstructive Pulmonary Disease

The American Journal of Managed Care® Launches Video Series “COPD Treatment Updates: Impact on Daily Life”

Retrieved on: 
Thursday, February 20, 2020
Science, Cardiology, Other Science, Research, Managed care, Health, Hospitals, Other Health, Pulmonology, Health, Medicine, Chronic lower respiratory diseases, Respiratory diseases, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, Respiratory disease, Pulmonary rehabilitation, Acute exacerbation of chronic obstructive pulmonary disease

The American Journal of Managed Care (AJMC), the leading multimedia peer-reviewed journal dedicated to issues in managed care, presents its most recent Peer Exchange panel discussion, COPD Treatment Updates: Impact on Daily Life.

Key Points: 
  • The American Journal of Managed Care (AJMC), the leading multimedia peer-reviewed journal dedicated to issues in managed care, presents its most recent Peer Exchange panel discussion, COPD Treatment Updates: Impact on Daily Life.
  • The video series features several experts in the field of chronic obstructive pulmonary disease (COPD), who discuss the latest in therapeutic developments for the treatment of COPD and considerations for coverage and utilization in daily practice.
  • This peer exchange will help all our viewers gain a better understanding of COPD and help them improve patient care in their practices.
  • Throughout this series, experts will review the current standard of care in COPD and burden this disease can cause patients.

The North America high-flow nasal cannula market is expected to reach US$ 4,261.14 Mn in 2027 from US$ 1,644.50 Mn in 2018

Retrieved on: 
Tuesday, February 18, 2020
Medical equipment, Medicine, Health, Respiratory therapy, Clinical medicine, Heated humidified high-flow therapy, Mechanical ventilation, Cannula, Nasal cannula, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease

The North America high-flow nasal cannula market is expected to reach US$ 4,261.14 Mn in 2027 from US$ 1,644.50 Mn in 2018.

Key Points: 
  • The North America high-flow nasal cannula market is expected to reach US$ 4,261.14 Mn in 2027 from US$ 1,644.50 Mn in 2018.
  • However, adverse effects or risk of high flow nasal cannula is likely to have a negative impact on the growth of the market in the coming years.
  • In 2018, the US high-flow nasal cannula market held the largest share of the North America high-flow nasal cannula market because it has highest COPD prevalence.
  • Chronic Obstructive Pulmonary Disease segment a largest market share of the high-flow nasal cannula market, by application in 2018.

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 3, 2020
Health, Other Health, Respiratory diseases, Pulmonology, Organ systems, Respiratory therapy, Chronic lower respiratory diseases, Obstructive lung disease, Respiratory disease, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Lung, Bronchitis, Acute exacerbation of chronic obstructive pulmonary disease

The "Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of mucus, difficulty in breathing, shortness of breath (initially with exertion), wheezing, chest tightness, and other respiratory symptoms.
  • The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.
  • The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

Retrieved on: 
Friday, January 24, 2020
Pulmonology, Chronic lower respiratory diseases, Respiratory system, Medicine, Obstructive lung disease, Respiratory therapy, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease, Chronic condition, Pulmonary disease, chronic obstructive, severe early-onset, COPD Awareness Month

The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.

Key Points: 
  • The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.
  • The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of COPD in the 7MM.
  • In the 7MM, epidemiologists forecast an increase in the total prevalent cases of COPD from 59,286,188 cases in 2018 to 67,185,113 cases in 2028 at an AGR of 1.33% during the forecast period.
  • - The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

Highmark Health, Allegheny Health Network and Johns Hopkins Medicine Expand Collaboration

Retrieved on: 
Thursday, January 16, 2020
Allegheny Health Network, Maternal–fetal medicine, Specialty, Health, Neonatology, COPD: Journal of Chronic Obstructive Pulmonary Disease, Medicine, Medical specialties

PITTSBURGH, Jan. 16, 2020 /PRNewswire/ --Highmark Health, Allegheny Health Network (AHN) and Johns Hopkins Medicine today announced an expanded collaboration between the organizations that will focus on gynecologic care and maternal fetal medicine, chronic obstructive pulmonary disease (COPD) and lung transplantation.

Key Points: 
  • PITTSBURGH, Jan. 16, 2020 /PRNewswire/ --Highmark Health, Allegheny Health Network (AHN) and Johns Hopkins Medicine today announced an expanded collaboration between the organizations that will focus on gynecologic care and maternal fetal medicine, chronic obstructive pulmonary disease (COPD) and lung transplantation.
  • AHN specialists in obstetrics, maternal-fetal medicine, neonatology and pediatrics will work with the Johns Hopkins team to meet the comprehensive health needs of such patients.
  • About the Allegheny Health Network:
    Allegheny Health Network (AHN.ORG), part of Highmark Health, is an integrated healthcare delivery system serving the Western Pennsylvania region.
  • The Network also serves as a clinical campus for Temple University School of Medicine, Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.

Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023 | Evolving Opportunities with AstraZeneca and Boehringer Ingelheim | Technavio

Retrieved on: 
Monday, January 6, 2020
Health, Cardiology, Pharmaceutical, Respiratory diseases, Pulmonology, Chronic lower respiratory diseases, Respiratory system, RTT, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, Respiratory disease, Bronchitis, Pulmonary disease, chronic obstructive, severe early-onset, Beclometasone/formoterol/glycopyrronium

View the full release here: https://www.businesswire.com/news/home/20200106005627/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200106005627/en/
    Technavio announced its latest market research report titled global chronic obstructive pulmonary disease (COPD) drugs market 2019-2023 (Graphic: Business Wire)
    Read the 124-report with TOC on Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Analysis Report by Product (Combination therapy and Monotherapy), Type (Chronic bronchitis and Emphysema), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2019-2023.
  • In addition, expanding research in curative approaches is anticipated to boost the growth of the chronic obstructive pulmonary disease (COPD) drugs market.
  • Major Five Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Companies:
    AstraZeneca operates the business in the Biopharmaceuticals segment.
  • Technavio has segmented the Chronic Obstructive Pulmonary Disease (COPD) Drugs market based on the product, type, and region.

Pulmonary Wellness Foundation Launches Innovative Mission to Address Gaps in Clinical Care, Patient Education for Millions With Respiratory Disease

Retrieved on: 
Wednesday, December 18, 2019
Philanthropy, Health, Hospitals, Managed care, Foundation, Cardiology, Medicine, Medical specialties, Health, Respiratory therapy, Respiratory diseases, Pulmonology, Respiratory disease, Pulmonary hypertension, Pulmonary fibrosis, COPD: Journal of Chronic Obstructive Pulmonary Disease, Physical therapy, Respiratory therapist

Dr. Noah Greenspan, DPT, a noted cardiopulmonary physical therapist and thought-leader in the pulmonary wellness arena, today announced the establishment of the Pulmonary Wellness Foundation .

Key Points: 
  • Dr. Noah Greenspan, DPT, a noted cardiopulmonary physical therapist and thought-leader in the pulmonary wellness arena, today announced the establishment of the Pulmonary Wellness Foundation .
  • Respiratory illnesses, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis (PF) and pulmonary hypertension (PH), affect millions of people across all ages and ethnicities.
  • An educated patient is our greatest ally in the fight against respiratory disease, Dr. Greenspan said.
  • The Pulmonary Wellness Foundation is a 501(c) (3) nonprofit organization designed to serve as the worlds most comprehensive and advanced pulmonary wellness hub and community for people living with pulmonary diseases.

New Pulmonary Rehabilitation Program is a Breath of Fresh Air for Those With Chronic Lung Disease

Retrieved on: 
Thursday, December 12, 2019
Pulmonology, Medicine, Clinical medicine, Chronic lower respiratory diseases, Respiratory therapy, Pulmonary rehabilitation, Respiratory disease, Bronchitis, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Pulmonary fibrosis, Lung

HOPEWELL, N.J., Dec. 12, 2019 /PRNewswire/ -- For people in the Mercer/Bucks County region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis and pulmonary fibrosis, Capital Health is launching its new Pulmonary Rehabilitation Program in December.

Key Points: 
  • HOPEWELL, N.J., Dec. 12, 2019 /PRNewswire/ -- For people in the Mercer/Bucks County region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis and pulmonary fibrosis, Capital Health is launching its new Pulmonary Rehabilitation Program in December.
  • "Collaboration is the key to the program's success, and participants see the benefits of this approach right from the start," said Dr. Diana Kolman, director of the new Pulmonary Rehabilitation Program at Capital Health and director of the Interventional Pulmonary Program.
  • Anyone considering the program should check with his or her insurance provider regarding coverage for pulmonary rehabilitation.
  • For more information about Capital Health's Pulmonary Rehabilitation Program, visit capitalhealth.org/pulmonaryrehab or call 609.537.6420 to schedule an appointment.

ALung Announces Continued Progress Towards Completion of Two Landmark Pivotal Trials

Retrieved on: 
Tuesday, December 3, 2019
Research, General Health, Medical devices, Hospitals, Clinical trials, Science, Surgery, Biotechnology, Nursing, Medical Supplies, FDA, Health, Medical specialties, Medicine, Health, Intensive care medicine, Chronic lower respiratory diseases, Respiratory therapy, Respiratory diseases, Mechanical ventilation, Chronic obstructive pulmonary disease, Extracorporeal carbon dioxide removal, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease

The VENT-AVOID pivotal trial is studying the avoidance or minimization of the need for mechanical ventilation in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AE-COPD).

Key Points: 
  • The VENT-AVOID pivotal trial is studying the avoidance or minimization of the need for mechanical ventilation in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AE-COPD).
  • The VENT-AVOID pivotal trial is now the worlds largest prospective Randomized Controlled Trial (RCT) ever conducted on the utilization of ECCO2R in AE-COPD with greater than 60 patients now enrolled.
  • ALung is the only company pursuing two major pivotal trials to validate the safety and efficacy of extracorporeal carbon dioxide removal therapy.
  • ALung Technologies, Inc. is a privately held Pittsburgh-based developer and manufacturer of innovative lung assist devices.

Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China

Retrieved on: 
Thursday, November 28, 2019
Drugs, Chemical compounds, Muscarinic antagonists, Organic compounds, Combination drugs, Indacaterol/glycopyrronium bromide, Quaternary ammonium compounds, Tertiary alcohols, Glycopyrronium bromide, Chronic obstructive pulmonary disease, Indacaterol, COPD: Journal of Chronic Obstructive Pulmonary Disease

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).
  • The list is approved nationally with the aim of providing basic medical coverage to China's population of 1.4 billion.
  • Glycopyrronium bromide and certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura.
  • "Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).